2017 Lifetime Achievement Award

Professor Bill Deakin

We are delighted to announce that the 2017 Lifetime Achievement Award will be presented to Professor Bill Deakin at the Conference Dinner at the Royal Hall, Harrogate, on Tuesday, 25 July.

Bill has been a dynamic and inspirational figure in British Psychopharmacology for over 25 years, his work has international recognition and he has been a huge supporter of the BAP throughout his career.

Bill graduated in Medicine at Leeds University in 1973. During his training, he was awarded an intercalated degree in Physiology, which stimulated his interest in neurobiology and behaviour. After graduating he specialised in psychiatry, training at the Clinical Research Centre at Northwick Park, London and the National Institute for Medical Research, Mill Hill. He received his PhD in 1981 from the University of London for work on how serotoninergic pathways in the rat brain regulate adaptive responses to stress. In the early 1980s he was appointed as Senior Lecturer in Psychiatry at the University of Manchester and in 1990 he was appointed to the position of Professor of Psychiatry, going on to found the Neuroscience

continued on page 2
and Psychiatry Unit which he has headed since 1997. Bill was instrumental in setting up the Manchester Wellcome Trust Clinical Research Facility of which he was the first director.

Bill's work has covered a wide range of areas. He has conducted research on 5HT pathways in volunteers and patients with anxiety, depression and antisocial behaviour. This established and confirmed the importance of these pathways in coping and resilience when faced with chronic difficulties as well as in addiction and social behaviour. Other work has related to the role of glutamate in schizophrenia based on post-mortem brain studies and magnetic resonance imaging. In recent years, he has conducted a series of clinical trials to investigate the role of novel agents, including the antibiotic minocycline and the anti-inflammatory drugs methotrexate and celecoxib, in improving clinical outcomes for people with schizophrenia and affective disorders.

Bill has over 200 refereed publications, an H-factor of 78 and over 20 000 citations. He has contributed many book chapters and presented at umpteen scientific meetings in the UK and abroad. Bill's work has also involved developing clinical guidelines, including the 2012 World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of schizophrenia.

Bill has played an extremely important role in British neuroscience and psychopharmacology, including serving on various Medical Research Council (MRC), Wellcome Trust and National Institute for Health Research (NIHR) Panels and Strategy Committees, as well as the Royal College of Psychiatrists' Academic Committee Task Force. He has been an NIHR Senior Investigator and experimental medicine lead of the UK Mental Health Research Network. Bill also has a prominent international presence through research collaborations and including involvement in the European College of Neuropsychopharmacology. In 2000 he was elected a Fellow of the Academy of Medical Sciences and in 2008 he was elected Foreign Corresponding Fellow of the American College of Neuropsychopharmacology (ACNP).

He has been an active and inspiring promoter of psychopharmacology through teaching and conference presentations, public engagement and through supervising and mentoring many of today's aspiring and established researchers in the field.

Bill has been a tireless and longstanding supporter of the BAP, playing a full part in its activities and regularly attending and speaking at BAP meetings and events throughout his career. He was instrumental in setting up the BAP Clinical Certificate (now in its 21st successful year) and has served both as a Council member and President (1996-99).

Warmest congratulations to Bill on behalf of the BAP Council.

---

**2017 Election for BAP Officers and Council Members**

The deadline for nominations for two Officer and two Council seats has now passed. Nominations, together with the nominee statements, are below.

All nominees are elected unopposed and will take up office after the AGM.

**Honorary General Secretary**

Maxine Patel ends her 3-year term.

Peter Talbot will be elected unopposed to the Honorary General Secretary post.

**Secretary for Non-Clinical External Affairs**

Paula Moran ends her 3-year term.

Sarah Bailey will be elected unopposed to the Secretary for Non-Clinical External Affairs post.

**Two Elected Council Member posts**

(Post 1) Sarah Bailey will retire

Michael Browning will be elected unopposed.

(Post 2) James Stone will retire

Tom Freeman will be elected unopposed.
Current Officers and Council
See website for biographies www.bap.org.uk/council

ELECTED OFFICERS

Professor Jo Neill
President

Professor Allan Young
President Elect

Professor Paul Harrison
Past President

Dr Elizabeth Tunbridge
Honorary Treasurer

Dr Mitul Mehta
Meetings Secretary

Dr Maxine Patel
Honorary General Secretary

Dr Oliver Howes
Secretary for Clinical External Affairs

Dr Paula Moran
Secretary for Non-Clinical External Affairs

ELECTED COUNCIL MEMBERS

Dr Sarah Bailey (Post 1)
Sarah will be elected unopposed to the Secretary for Non-Clinical External Affairs post for a 4-year term

Dr James Stone (Post 2)

Dr Carmine Pariante (Post 3)

Dr Rachel Upthegrove (Post 4)
(filling a casual vacancy until July 2018)

Professor Ciara McCabe (Post 5)

Dr Peter Talbot (Post 6)
Peter will be elected unopposed to the Honorary General Secretary post for a 4-year term

Dr Paul Stokes (Post 7)

Dr Angela Roberts (Post 8)

NON-VOTING MEMBERS OF COUNCIL

Professor David Nutt
Editor-in-Chief of BAP Journal of Psychopharmacology

Dr Hamish McAllister-Williams
BAP Director of Education

OTHER VOTING MEMBERS OF COUNCIL

Jonas Eberhard
Candidates’ Biographies and Statements

Peter Talbot  
University of Manchester  
Proposer: Professor Jo Neill  
Seconder: Dr Maxine Patel

I qualified in Medicine from the University of Bristol, and completed my specialist clinical training and MD in Psychiatry in Northern Ireland, the country of my birth. My postdoctoral research training was in Positron Emission Tomography (PET) neuroimaging under the supervision of Marc Laruelle at Columbia University in New York, followed by appointment as Assistant Professor in Psychiatry there in 2004. I joined the University of Manchester in 2005 and am currently Senior Lecturer in Molecular Neuroimaging and Associate Director of the Wolfson Molecular Imaging Centre. My primary research interest is the use of PET to investigate abnormal brain mechanisms in severe mental illness, particularly psychosis, affective disorders and impulsivity. I am active in neuroscience and psychopharmacology teaching both locally (Lead for undergraduate and postgraduate modules; President Elect, Manchester Medical Society Psychiatry Division) and nationally for the BAP (Course Organiser for the Schizophrenia Module; lecturer on the Affective Disorders Module and Depression Masterclass). I am an Honorary Consultant Psychiatrist with Greater Manchester Mental Health NHS Foundation Trust and Director of the Specialist Service for Affective Disorders, a regional tertiary-level NHS clinic.

I have been an active member of BAP for over 17 years (BAP Certificate in Psychopharmacology, 2001), serving on Council since 2015. Throughout my training I found the BAP’s Education & Training programmes invaluable and as a researcher I greatly value the Summer Meeting as an opportunity to share cutting edge research with clinical and preclinical colleagues. I am well aware of the importance of BAP in providing informal support and mentorship especially to younger members starting out in their careers. For the last 10 years I have been actively involved in a wide range of BAP teaching programmes - I taught on the Masterclass in Schizophrenia 2007-2012, was Scientific Editor for its on-line CPD module until 2012, have been Course Organiser and lecturer on the Schizophrenia Module of the Clinical Certificate since 2012, and for the last 4 years I have also taught on the Affective Disorders Certificate Module and Depression Masterclass. Being on Council for the last 2 years has given me an insight into the workings of the association and the importance of the huge amount of work necessary behind the scenes. I would be delighted to be able to serve the BAP further as Honorary General Secretary.

My work as an academic involved in clinical and basic science research, plus my clinical work as an Honorary NHS Consultant, means I am well placed to represent the full BAP membership as General Secretary. Membership numbers are static and even falling across a range of professional associations, and I intend to work hard to assist the President, Council and Executive Officer with plans to maintain and expand the BAP’s membership. Keeping effective records and upholding the necessary legal requirements are important parts of the role and I believe I can bring enthusiasm and attention to detail to the post. I will continue to work to promote and maintain the role of the BAP as provider of choice for high-quality information, education and training for clinicians at all levels – as well as to patients, carers and the public. One of the BAP’s very great strengths is its multidisciplinary nature – Clinical Psychiatry, Pharmacy, Preclinical and Industry. I believe that good medicine needs strong collaboration between these disciplines of the highest scientific and ethical standards, and I will be active in seeking to maintain and promote this cross-disciplinary interaction among the membership.

Sarah Bailey  
University of Bath  
Proposer: Professor Jo Neill  
Seconder: Dr Paula Moran

I am currently a senior lecturer in the Department of Pharmacy and Pharmacology, University of Bath. My research focuses on understanding molecular mechanisms underlying
Michael Browning  
*Department of Psychiatry, Oxford*

**Proposer:** Professor Catherine Harmer  
**Seconder:** Dr Hugh Marston

The BAP fulfils a unique role in the UK. Its annual conference is the key national forum in which biological psychiatric research is presented, meaning that it is the best place to present your own work and to find out what others in your area are doing. Its educational program, which includes clinical masterclasses and the preclinical psychopharmacology course, provides evidence based information for both clinicians and preclinical scientists. Lastly, the BAP’s public engagement activities help to promote a balanced understanding of the role of psychopharmacology. As a result, the BAP has become an essential component in supporting and encouraging the development of young researchers and in representing psychopharmacology at the national level.

Over the many years I have been a member of the BAP it has supported me to attend overseas conferences as well as providing a national platform to present my work. More importantly than this, most of the researchers and research active clinicians I know in the UK I have met at the BAP conference. Recently I have started trying to pay back some of the debit I owe the BAP—as well as regularly attending and presenting my work at the conference, I have spoken at BAP masterclasses and lecture on the certificate in non-clinical psychopharmacology course.

I am a clinical researcher with a specific interest in the emotional disorders and the mechanisms by which the treatments of these illnesses exert their effects. I am based in the Department of Psychiatry in Oxford. My current research includes both mechanistic and treatment development studies. As well as working in the NHS and academia I have previously worked in industry and so have broad experience of both psychopharmacology research as well as the ultimate clinical application of that research.

If elected to the council I will work 1) to support the development of early career researchers (both financially and professionally), 2) to support the...
Statement of Intent

Nine years ago, the BAP Summer Meeting was the first conference I ever attended, giving me the opportunity to present my first independent research project as an undergraduate student. I was very impressed by the warm, open and academically stimulating environment and wide scope of clinical, pre-clinical and translational research on offer. I have voted with my feet by returning every single year since 2010 – I am hooked! I am very grateful for the support I have received from the BAP, by contributing to my training and development through its excellent meetings, travel bursaries (2010, 2012, 2016) awards (2013, 2015) and inviting me to speak during the sessions (2013, 2016). I am proud to be a member of such a tremendous organisation principled by inclusion, diversity and democracy. I am aware that its success rests on the tireless contribution of the fantastic BAP team, officers, council and members. With this in mind, I would now like to support the BAP with my own time, energy and enthusiasm as a member of council.

BAP membership is currently decreasing. For this reason, I feel it is important to consider how to maximise the benefits of membership (and progression between training, early-career and full membership) to attract and retain people in the long-term. In particular I would like to increase involvement and incentives for junior members, as they are the future of the BAP. For example, including PhD candidate speakers in the post-doctoral symposium could enhance their early investment in the BAP, and would open the scheme to a wider pool of applicants. I would also like to explore new training opportunities in addition to the in vivo training initiative. For example, an exchange programme between PhD students (working on overlapping themes in clinical and pre-clinical labs) could encourage collaboration across disciplines and translational research.

I was awarded a BAP public communication prize for my contribution to television, radio, news, talks and interactive events in schools, museums and festivals. I have also helped to disseminate BAP events and issues arising from them to professional bodies (British Psychological Society) and academic journals (The Lancet Psychiatry). I would like to enhance the media presence of the BAP further through its website, press releases, public events and collaboration with the Science Media Centre.
Harrogate International Centre
King’s Road, Harrogate

Sun 23rd to Wed 26th July 2017

Highlights

9 invited symposia covering cutting-edge clinical and non-clinical psychopharmacology:

- Personalized pharmacological treatments for depression: Will big data achieve what clinicians can’t?
- The psychopharmacology of emerging calcium channel targets
- Behavioural and substance addictions: Similarities and differences
- Adverse and beneficial effects of cannabinoids - new insights from genetics and clinical trials
- The role of brain connectivity in brain disorders and their treatment
- Psychopharmacology of the older and, almost certainly, degenerating brain
- Treatment of dysfunction in hot and cold cognition in mood disorders
- The brain-gut axis: Breaking the dichotomy between physical and mental health
- Biomarkers of treatment response for schizophrenia and bipolar affective disorder: Latest updates

Guest Lecture presented by Professor Sir Robin Murray

Facts about psychosis that (most) psychopharmacologists prefer to ignore

Preclinical Workshop

How can we refine preclinical psychopharmacology?

Post-Doc Symposium

Treatments in depression - new insights for an ongoing problem

Trainees’ Workshop

This year the overarching theme will be “How to …”

How to use fellowships to advance your career

Professor Jeremy Hall (Cardiff)

How to publish

Professor Paul Harrison (Oxford)

How to build a career in the pharmaceutical industry

Dr Jennifer Li (Lilly)

The loneliness of the long distance Psychopharmacologist. How to interact with different scientific disciplines

Dr Paula Moran (Nottingham)

Short Oral Sessions

- Mechanisms of anxiety and its treatment
- Circuits in schizophrenia
- Regulation and relevance of inflammation in affective disorders

Poster Sessions

We look forward to almost 170 posters being presented this year. There will also be interactive screens placed around the exhibition hall where you can also view all posters.

PLUS

Satellite Symposia and Special Sessions

Welcome Reception and Disco

Conference Dinner at The Royal Hall

An app will be available with full details of the programme and abstract book.
Applied Clinical Science Stream

Depression: Which treatment and for whom

BAP is pleased to announce that our 2017 summer meeting will include an “Applied Clinical Science” stream. This stream is of particular relevance to trainees, staff grade and consultant psychiatrists and mental health pharmacists. In addition to providing high quality up-to-date psychopharmacology CPD for clinicians, the stream will highlight insights into future developments in our understanding of mental illness and its treatment.

Treatment options for treatment resistant depression

Sunday 23 July 12:00 – 16:45
Queen’s Suite 1

Chair – Allan Young, King’s College London

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>Allan Young, King’s College London</td>
</tr>
<tr>
<td>13:15 – 13:45</td>
<td>‘Standard’ medication options and when should non-standard options be considered?</td>
</tr>
<tr>
<td></td>
<td>Hamish McAllister-Williams, Newcastle University</td>
</tr>
<tr>
<td>13:45 – 14:05</td>
<td>Medications targeting dopaminergic neurotransmission</td>
</tr>
<tr>
<td></td>
<td>Alan Currie, Newcastle University</td>
</tr>
<tr>
<td>14:05 – 14:25</td>
<td>Running a ketamine treatment service in the NHS</td>
</tr>
<tr>
<td></td>
<td>Rupert McShane, University of Oxford</td>
</tr>
<tr>
<td>14:25 – 14:45</td>
<td>Q&amp;A with the Panel</td>
</tr>
<tr>
<td>14:45 – 15:15</td>
<td>Refreshments</td>
</tr>
<tr>
<td>15:15 – 15:35</td>
<td>tDCS</td>
</tr>
<tr>
<td></td>
<td>Cindy Fu, King’s College London</td>
</tr>
<tr>
<td>15:35 – 15:55</td>
<td>TMS</td>
</tr>
<tr>
<td></td>
<td>Michael Craig, King’s College London</td>
</tr>
<tr>
<td>15:55 – 16:15</td>
<td>VNS</td>
</tr>
<tr>
<td></td>
<td>John Rush, Duke University</td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td>Q&amp;A with the Panel</td>
</tr>
<tr>
<td>16:45</td>
<td>Refreshments</td>
</tr>
</tbody>
</table>

www.bap.org.uk/BAP2017
A framework for a regulated market for cannabis in the UK: Recommendations from an expert panel

In 2015, the Liberal Democrats announced their intention to set up an expert panel to look into how a legal, regulated cannabis market could function in the UK. Transform’s Senior Policy Analyst, Steve Rolles, was appointed as chair of the panel, which also included Chief Constable of Durham Mike Barton, Professor David Nutt, Professor Fiona Meahsam, Professor Harry Sumnall, Niamh Eastwood of Release, and former Chief Constable of Cambridgeshire Police Tom Lloyd.


Professor Val Curran was interviewed by World at One on its release, which can be listened to at http://www.bbc.co.uk/programmes/b08p5lg4.

BAP at RCPsych

This year’s International Congress of the Royal College of Psychiatrists will take place in Edinburgh. On Monday 26th June, Dr Maxine Patel will chair a session on behalf of the BAP entitled “Off-label prescribing: A journey without Maps?”. Professor David Baldwin will outline the key concepts and considerations followed by Dr Aditya Sharma who will focus on the BAP position statement on off-label prescribing of psychotropic medication to children and adolescents. Finally, Dr Liz McDonald will consider prescribing in pregnancy.

The BAP stand will also be at the Congress, so do come along and say hello.

MARC MRC Addiction Research Clinical Training Program

Are you a clinician? Are you looking to undertake a PhD to build your academic career?

The MRC Addiction Research Clinical (MARC) Training scheme has PhD positions available. Please contact us now if you are interested and want to know more – even if you would not want to start until next year or later. We will work with you to develop your project.

The MRC Addiction Research Clinical (MARC) Training programme is led by Prof Anne Lingford-Hughes at Imperial College London, with Prof Colin Drummond at King’s College London and Prof Matt Hickman at University of Bristol. The vision of the MARC programme is to develop the future UK clinical research leaders in addiction to build and sustain capacity in this vital area of clinical neuroscience and address the gap in clinical research capacity in the addictions field in the UK. MARC can support clinicians (eg psychiatrists, psychologists etc) to undertake a PhD to train in a range of research approaches and techniques to effectively translate basic and epidemiological evidence into the clinical environment using early (T1, T2) experimental medicine studies in patients for the benefit of clinical populations and their treatment.

See http://www.imperial.ac.uk/medicine/mrc-addiction-research-clinical-training/ for more information and email anne.lingford-hughes@imperial.ac.uk or colin.drummond@kcl.ac.uk or matthew.hickman@bristol.ac.uk
BAP at the BNA Festival of Neuroscience 2017

BAP was in full force at the British Neuroscience Association Festival of Science 2017 in Birmingham in April. In addition to many of our members giving presentations throughout the festival we sponsored a symposium “Microglia, neuroinflammation and psychiatric disease: biomarkers and therapeutic potential which was chaired by Paula Moran (University of Nottingham) and Carmine Pariente (Kings College London). Neuroinflammation is increasingly recognized as an important factor in a range of psychiatric disorders. Speakers gave excellent presentations despite an unsettled giant digital clock counting down right in front of the podium! Hugh Perry (University of Southampton) gave an impressive overview and an update on his work in Alzheimer’s Disease, Irene Kneusel (Roche, Switzerland) elegantly outlined the opportunities and challenges in the field from an industry perspective, Carmine Pariente (Kings College London) reviewed his groups many contributions to identifying Biomarkers of inflammation in treatment response in both psychosis and depression. Anthony Vernon (Kings College London) presented compelling new data on preclinical models using transcriptional profiling and structural magnetic imaging. The session was really well attended and prompted many excellent questions and a notably lively discussion session.

Fundamentals of Clinical Psychopharmacology

Fundamentals of Clinical Psychopharmacology provides up-to-date, evidence-based and unbiased information about psychopharmacology. It spans the range of the discipline, from mode of action and side effects of drugs to meta-analyses of clinical trials. It is anchored to practice guidelines produced by the UK National Institute for Health and Care Excellence (NICE) and the British Association for Psychopharmacology (BAP). Care has been taken to provide an international perspective that makes it equally useful to practitioners in the US and other countries.

Members’ Activities

A showcase for the media and public engagement activities of BAP members.

Following are some of the latest members’ activities over the past few months. All members’ activities, with links, can be found at www.bap.org.uk/members

Tom Freeman 10th January 2017

Can we make cannabis safer?

Tom and co-author Amir talk to Editor Niall Boyce about cannabis harm reduction

Ciara McCabe 25th February 2017

The Emotional Brain: The 14th Oxford Brain Day

Ciara speaks about her work on depression and antidepressants treatments for Oxford Brain Day

Val Curran 12th May 2017

A framework for a regulated market for cannabis in the UK: Recommendations from an expert panel

Professor Val Curran was interviewed by World at One on the release of the framework for a regulated market for cannabis in the UK

Have you recently engaged with the public in science via the media or public events?

As you may be aware, both the Medical Research Council and the Wellcome Trust advocate engagement with the public regarding scientific and medical research, and BAP is keen for members to engage with the media, so that we can share our important research findings with the public, including enthusiastic students and trainees.

We would like to invite you to share your most recent media activities with us, so that we can disseminate them to the public through our website and social media.

In particular we are looking for media articles, video interviews, podcasts, websites and blogs.

Please send any links or other engagement with the media to Sarah Channing-Wright (sarah@bap.org.uk).

2017 Membership Subscriptions

Members who do not pay their annual subscription by Standing Order will by now have received five requests for payment to be made by alternative means.

Those who remain unpaid on 30 June will be removed from the membership list so that correct figures can be presented at the AGM in Harrogate on 24 July.
Education and Training

In line with one of its key aims, the BAP provides a broad range of education and training for health care professionals and researchers. This is provided in various formats to cater for needs and learning styles.

Education aimed at health care providers

BAP clinical educational material is primarily aimed at providing continuing professional development (CPD) for psychiatrists, including trainees. However the material is also relevant for General Practitioners (especially those with a special interest in mental health), Mental Health Pharmacists and nurses and pharmacists with prescribing responsibilities.

The centre piece of BAP Clinical education is the Masterclasses. The relationship between these are the other educational meetings and material is shown in the figure below.

If you prefer face to face teaching, then the Masterclasses provide an update on a broad range of subjects with the option of registering for one to three days on the course run twice a year in London. In addition to didactic lectures there are extensive opportunities for questions during a number of panel discussion sessions. For those looking for highly specialised teaching with even more opportunity for discussion in small groups, there are a range of Clinical Certificate modules to choose from. BAP face to face educational events are extremely popular and almost always sell out well ahead of time. A new BAP initiative is the introduction of an ‘Applied Clinical Science Stream’ to the Association’s annual scientific conference. This is designed to provide a mixture of CPD and the science around the management of mental illness, focusing on topical issues.

For those after an easy to use and cost effective means of staying up to date there is the BAP Online CPD Resource. This provides the most systematic and comprehensive coverage of psychopharmacology of any of the BAP’s educational initiatives. For people
who prefer a more traditional medium there is the prize winning textbook 'Fundamentals in Clinical Psychopharmacology' now in its fourth edition. This is particularly aimed at supporting the development of a solid pharmacological basis to prescribing. As such it can act as a foundation for all of the other clinical educational options.

**BAP guidelines** provide readable summaries of the current evidence base and succinct recommendations for clinical practice. Whenever possible, on the production/revision of a guideline, BAP organises a **BAP Guideline Meeting** to review the new document and discuss how this relates to other BAP and NICE guidelines, a great way of keeping on top of changing recommendations for clinical practice.

---

**Education aimed at researchers**

The cornerstone of training for non-clinical psychopharmacologists is the **Certificate**. This provides training in a range of topics as well as providing career advice. It is particularly appropriate for PhD students but also Research Associations and Post-doctoral researchers, particularly if switching research area. BAP also runs a specific **in vivo Training Initiative** in response to concerns around dwindling expertise in animal behavioural pharmacology and related research. This is complemented by the **InVivoStat Statistical Analysis** course designed for all pre-clinical researchers.

---

**ONLINE CPD RESOURCE**

A high quality, up-to-date resource taught by top experts in their field

- Schizophrenia
- Substance Misuse Including Comorbidity
- Bipolar Disorder
- Perinatal Disorders
- ADHD Focussing On Adult
- Depression
- Anxiety Disorders
- Sleep
- Old Age
- Child and Adolescent*
- General Psychopharmacology

Reviews of recent psychopharmacology papers, regularly updated

**PLUS**

- Multiple Choice Questions, printable certificate on completion and reading lists

For more information and to subscribe go to www.bap.org.uk/onlinecpd

*MCQs not currently available for this module

---

For non-members:

£120 per year

For members and those who have registered or attended recent BAP meetings/courses:

£60 per year

For multiple users (10+):

£45 per year

Also available on iPad
Prescribing for women with mental health problems in the context of pregnancy and breastfeeding is an ongoing challenge for both clinicians and the women themselves, because of the limited amount of evidence around the risks and benefits associated with the untreated disorders and the different therapeutic options. This conference introduces the first BAP Guidelines on this topic, and comprises speakers from the group who have developed this document and who are experts in its clinical, research and policy implications. The meeting will include state-of-the art and pragmatic updates, with key recommendations for the management of specific disorders, and will be an excellent educational opportunity for primary care doctors as well as specialists and allied professionals in psychiatry, pediatrics, obstetrics, midwifery, and related disciplines. This is an essential meeting for all those with an interest in treating mental health problems in the perinatal period.

Hallam Conference Centre, 44 Hallam St, London, W1W 6JJ
Tuesday 3rd October 2017

09:00 Registration and coffee

Morning Session

**Chairs:** Hamish McAllister-Williams, Newcastle University and Louise Howard, King's College London

09:30 Introduction **Hamish McAllister-Williams**
09:45 UK perinatal guideline landscape **Roch Cantwell** (University of Glasgow)
10:15 BAP Perinatal Guidelines: Overview and general principles **Hamish McAllister-Williams**
10:45 Coffee
11:15 Depression **Ian Jones** (Cardiff University)
11:45 Anxiety disorders and insomnia **David Baldwin** (University of Southampton)
12:15 Q&A with panel
12:45 Lunch

Afternoon Session

**Chairs:** Carmine Pariante, Institute of Psychiatry, London and Trudi Seneviratne, Chair of the Perinatal Faculty of RCPsych, Bethlem Royal Hospital, London

13:45 Introduction and relevance of the new BAP guidelines **Trudi Seneviratne**
13:50 Schizophrenia **Hind Khalifeh** (St Thomas’s Hospital, London)
14:20 Bipolar disorder **Angelika Wieck** (North West Perinatal Mental Health Service, Manchester)
14:50 Coffee
15:20 Substance Misuse **Anne Lingford-Hughes** (Imperial College, London)
15:50 Panel Q&A
16:20 Conclusions and end of meeting

Book online at [www.bap.org.uk/guidelinesmeeting](http://www.bap.org.uk/guidelinesmeeting)
Download the guidelines at [www.bap.org.uk/perinatalguidelines](http://www.bap.org.uk/perinatalguidelines)
News from CMHP

Making connections

The College of Mental Health Pharmacy is building its strategic partnerships and reaching out to increasing numbers of pharmacists and pharmacy technicians with an interest in mental health. Recent examples include:

- Several members of CMHP have worked with Centre for Pharmacy Postgraduate Education (CPPE) in developing their Learning Disability (LD) education materials, including Council members Nikki Holmes and Steve Buckley – Nikki peer-reviewed the LD Distance Learning package, and Steve who recorded a presentation based on the LD work he’s been doing with Trafford CCG.

- CMHP is delighted to have accredited the Postgraduate Psychiatry Pharmacy Programmes of Aston University. Accreditation gives students the assurance that by following an accredited programme, they will gain valuable experience and insight for pursuing a career in mental health pharmacy.

- Where the opportunity arises, the College is exhibiting at events – to promote the work of the CMHP and to encourage interest in mental health pharmacy, for example at the recent Clinical Pharmacy Congress in London in May.

For more information about our work, please visit our website: www.cmhp.org.uk

8th International Psychiatric Pharmacy Conference – ‘A Wider Perspective’

The CMHP international conference takes from 13-15 October at The Midland, Manchester. The theme this year is ‘A Wider Perspective’: looking at how mental health can be affected by outside influences such as physical health. Excitement is building as preparations continue, with more speakers confirmed and delegate registrations coming in.

The call for posters is open until 23 June. For more information please see: http://www.cmhp.org.uk/conference/conference-2017/oral-presentations-posters/

To register for the conference please visit the conference page at: http://cmhpconference.co.uk/

19th Meeting of the International Society for Serotonin Research

“Serotonin on the Wild Atlantic Way”

University College Cork, Cork, Ireland, July 15–19, 2018

The ISSR currently boasts a membership of over 350. Conferences are held biennially, and attract serotoninologists from all over the world. A special feature of these meetings are the plenary lectures, named after the titans who contributed to the discovery of serotonin – The Irvine Page (established in 1990), Maurice Rapport (established in 2006) and Paul Vanhoutte (established in 2016). The meeting is comprised of short focused symposia, where renowned experts, as well as junior investigators, address current advances in the field. Topics covered include normal brain function, development, aging, CNS disorders, addiction, cardiovascular function, digestive processes, immune function and pain; and are translational, comprising molecular pharmacology, neurochemistry, animal behaviour and clinical approaches. The conference will be held at Devere Hall, University College Cork, Cork City, Ireland at the beginning of the famous Wild Atlantic Way.

http://www.wildatlanticway.com/

Cork is the second largest city in the Republic of Ireland with a unique character that derives from a combination of the people, topography, culture, and its location on the River Lee and is a University city where both ‘Town and Gown’ are integrated.

Plenary Speakers:

Irvine Page Lecturer: Dr Patricia Gaspar, Institut du Fer a Moulin, Paris

Maurice Rapport Lecturer: Prof Mark Geyer, University of California San Diego

Paul Vanhoutte Lecture: Prof Kathryn Cunningham, The University of Texas Medical Branch

Further meeting details will be posted on our website (http://www.serotoninclub.org) as they become available and registration will open January, 2018.

If you require further information please contact: kevin.fone@nottingham.ac.uk
We are delighted to introduce new international journal *Brain and Neuroscience Advances*, published by SAGE and wholly owned by the BNA.

**Broad scope, multidisciplinary journal**

**High profile international editorial board** and **high quality** peer review

**International gold open access journal** with no barriers to access

Time from submission to first decision = **20 days**

Time from acceptance to publication = **20 days**

Introductory **50% discount** on article processing charge & **no page charges**

bit.ly/SAGEBNA

*Special launch issue available at BNA2017: Make sure you get your free copy!*
The British Pharmacological Society’s flagship annual meeting attracts over 1,000 scientists each year from the UK and around the world. The Society is pleased to announce initial details for this year’s meeting, which will feature symposia on a range of topics, including those supported by our Neuropharmacology Affinity Group:

- A new look at imidazolines, their receptors and emerging therapeutic applications
- Pharmacological strategies for disease modification in the treatment of neurodegenerative proteinopathies
- Sigma-1 receptors as therapeutic targets

The latest research from across the whole spectrum of pharmacology will be the focus for plenary lectures, oral communications, and poster sessions. As with previous years, there will also be invaluable opportunities for participants to network with pharmacologists from across the world.

The British Pharmacological Society’s flagship annual meeting attracts over 1,000 scientists each year from the UK and around the world. The Society is pleased to announce initial details for this year’s meeting, which will feature symposia on a range of topics, including those supported by our Neuropharmacology Affinity Group:

- A new look at imidazolines, their receptors and emerging therapeutic applications
- Pharmacological strategies for disease modification in the treatment of neurodegenerative proteinopathies
- Sigma-1 receptors as therapeutic targets

The latest research from across the whole spectrum of pharmacology will be the focus for plenary lectures, oral communications, and poster sessions. As with previous years, there will also be invaluable opportunities for participants to network with pharmacologists from across the world.

For further information about attending or presenting at Pharmacology 2017, please email meetings@bps.ac.uk or visit www.bps.ac.uk/pharmacology2017.